SMARCB1 deficiency has been mainly described in mesenchymal tumors, but next-generation sequencing studies have subsequently shown that SMARCB1 alterations are also found in a subset of carcinomas, although at low frequency. Here, SMARCB1 is linked to mesenchymal cell neoplasm.